GlaxoSmithKline's MATINEE trial shows Nucala reduces COPD exacerbations in 104-week study.

GlaxoSmithKline (GSK) announced positive results from its phase III MATINEE trial of Nucala (mepolizumab) for chronic obstructive pulmonary disease (COPD). The trial showed a significant reduction in moderate to severe exacerbations in patients receiving Nucala alongside maintenance therapy compared to a placebo over 104 weeks. Nucala, previously approved for severe asthma, targets interleukin-5 to combat inflammation. Further analysis and results will be shared at future scientific meetings.